Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens

doi:10.1007/s00432-021-03708-1

	Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens
	Cao, Fei; Zheng, Jiaping; Luo, Jun; Zhang, Zhewei; Shao, Guoliang
刊名	JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
	2021-07-24
关键词	Regorafenib plus DEB-TACE CRLM Treatment response Prognosis Adverse events
ISSN号	0171-5216
DOI	10.1007/s00432-021-03708-1
通讯作者	Shao, Guoliang(guofu330@163.com)
英文摘要	Objective This study aimed to evaluate the efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization (DEB-TACE) versus regorafenib monotherapy in colorectal cancer liver metastases (CRLM) patients who failed standard treatment regimens. Methods Totally, 76 eligible CRLM patients were analyzed, among which 42 patients received regorafenib monotherapy (as regorafenib group) and 34 patients received regorafenib plus DEB-TACE (as regorafenib plus DEB-TACE group). Results Objective response rate (35.3% versus 7.1%, P=0.002) and disease control rate (76.5% versus 47.6%, P=0.011) were both increased in regorafenib plus DEB-TACE group compared with regorafenib group; meanwhile, negative conversion rate of carcinoembryonic antigen (66.7% versus 28.6%, P=0.008) after treatment was elevated in regorafenib plus DEB-TACE group compared with regorafenib group. Notably, progression-free survival (PFS) (median value: 7.6 versus 4.1 months, P<0.001) and overall survival (OS) (median value: 15.7 versus 9.2 months, P<0.001) were both higher in regorafenib plus DEB-TACE group compared with regorafenib group. Furthermore, liver function indexes (alanine transaminase, aspartate aminotransferase, and cholinesterase levels) after treatment were all similar between the two groups (all P>0.05). In addition, the occurrences of upper abdominal distending pain (P<0.001), nausea and vomiting (P=0.002) and fever (P=0.002) were higher in regorafenib plus DEB-TACE group compared with regorafenib group, while the majority of these adverse events were mild and tolerable. Conclusions Regorafenib plus DEB-TACE is superior to regorafenib monotherapy regarding treatment response, PFS and OS, while induces tolerable post-embolization syndrome in CRLM patients who fail standard treatment regimens.
资助项目	Medicine and health discipline platform project of zhejiang province[2018RC019] ; Medicine and health discipline platform project of zhejiang province[2020KY483]
WOS关键词	TACE ; MELANOMA
WOS研究方向	Oncology
语种	英语
出版者	SPRINGER
WOS记录号	WOS:000676080100001
资助机构	Medicine and health discipline platform project of zhejiang province
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/123269]
专题	中国科学院合肥物质科学研究院
通讯作者	Shao, Guoliang
作者单位	Chinese Acad Sci, Inst Basic Med & Canc IBMC, Zhejiang Canc Hosp, Dept Intervent Radiol,Canc Hosp,Univ Chinese Acad, 1 Banshan Dong Lu, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Cao, Fei,Zheng, Jiaping,Luo, Jun,et al. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY,2021.
APA	Cao, Fei,Zheng, Jiaping,Luo, Jun,Zhang, Zhewei,&Shao, Guoliang.(2021).Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY.
MLA	Cao, Fei,et al."Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens".JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021).